R&D News | pharmaphorum

News

ASCO 25: Roche places Itovebi marker in breast cancer

Roche's Itovebi has become the first PI3K inhibitor to extend survival in HR-positive, HER2-negative breast cancer with a PIK3CA mutation.

News

RFK Jr spreading 'harmful myths' on Alzheimer's research

The Alzheimer's Association has hit out at "inaccurate and dangerous fabrications" by HHS Secretary Robert F Kennedy Jr about NIH dementia research.

News

Sanofi makes Alzheimer's play with Vigil takeover

Sanofi bids to add a drug candidate for Alzheimer's disease to its neurology pipeline via the acquisition of US biotech Vigil Neuroscience.

News

US imposes limits on COVID-19 boosters and new jabs

The FDA has introduced a stricter set of policies around COVID-19 vaccines, including requiring clinical trials for new shots in some cases.

News

Beckley Psytech's chief scientific and medical officer Dr Rob Conley

Beckley's psychedelic med inches forward in depression

UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.

News

UK trumpets £1bn investment plan from BioNTech

BioNTech has said it will commit up to £1bn in investment in the UK over the next decade, in what has been described as a "template" for the sector.

ASCO 25: Roche places Itovebi marker in breast cancer

RFK Jr spreading 'harmful myths' on Alzheimer's research

Sanofi makes Alzheimer's play with Vigil takeover

US imposes limits on COVID-19 boosters and new jabs

Beckley's psychedelic med inches forward in depression

UK trumpets £1bn investment plan from BioNTech

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks